Last reviewed · How we verify
NCT07148752
Evaluation of Resveratrol and Its Loaded Nanoparticles on Acanthamoeba
trial in Corneal Ulcer Caused by Acanthamoeba in 50 participants. Not yet recruiting.
30 October 2028
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 15 October 2025 |
| Primary completion | 30 October 2028 |
| Estimated completion | 1 November 2028 |
Conditions studied
- Corneal Ulcer Caused by Acanthamoeba — all drugs for Corneal Ulcer Caused by Acanthamoeba →
Sponsor
Assiut University
Who can join
Eligibility, any sex, with Corneal Ulcer Caused by Acanthamoeba. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acanthamoeba is a free-living amoeba responsible for severe human infections. There are at least twenty-two different genotypes of Acanthamoeba (T1-T22). T4 is the most common virulent genotype, mainly Acanthamoeba castellani and Acanthamoeba polyphaga. Proper treatment still represents a challenge for healthcare professionals.So, we need novel therapeutic strategies, including newer drugs and/or drug delivery systems that can overcome the developing drug resistance as well as have minimal toxicity to human cells. There is a new approach in the treatment of parasitic disease by using nanotechnology and natural compounds as plant extracts. The current study aims to evaluate the therapeutic potential of resveratrol, both in its free form and when loaded on nanoparticles, against clinically isolated Acanthamoeba strains obtained from patients with persistent AK or corneal ulcers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07148752
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07148752 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 29 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07148752.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing